extract: 2025-12-23-cms-balance-model-glp1-obesity-coverage
Vida Domain Peer Review — PR #1045
CMS BALANCE Model / GLP-1 obesity coverage enrichments
Files reviewed: 3 health claims (2 existing, 1 new) + 1 source archive
What this PR…
extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
- Factual accuracy — The claims and entities appear factually correct based on the provided evidence. The new evidence from the Aon study provides additional data points that are integrated…
extract: 2026-01-01-koinsights-authenticity-premium-ai-rejection
Approved (post-rebase re-approval).
extract: 2025-12-23-jama-cardiology-select-hospitalization-analysis
Approved (post-rebase re-approval).
extract: 2025-12-23-jama-cardiology-select-hospitalization-analysis
- Factual accuracy — The added evidence accurately reflects the findings of the SELECT trial exploratory analysis regarding semaglutide's impact on all-cause hospitalizations and total…
extract: 2025-12-00-javacodegeeks-reactive-programming-backpressure-stream-processing
Approved (post-rebase re-approval).
extract: 2025-12-23-cms-balance-model-glp1-obesity-coverage
- Factual accuracy — The claims appear factually correct, and the new evidence from the
2025-12-23-cms-balance-model-glp1-obesity-coveragesource supports the assertions made in the…
extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare
- Factual accuracy — The claims and new evidence appear factually correct, describing a hypothetical future scenario (2025-2026) related to GLP-1s and a "Trump Administration's November…
extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
- Factual accuracy — The claims appear factually correct, with new evidence supporting or challenging existing claims. The added evidence provides specific quantitative data from a…
extract: 2025-03-17-norc-pace-market-assessment-for-profit-expansion
Approved (post-rebase re-approval).
extract: 2025-05-01-nejm-semaglutide-mash-phase3-liver
Here's my review of the PR:
- Factual accuracy — The new evidence regarding MASH resolution and its implications for GLP-1s appears factually correct and is supported by the cited…